Skip to content

The ilioinguinal-transversus abdominis plane (I-TAP) nerve block with liposomal bupivacaine for cesarean delivery analgesia: A randomized controlled trial

The ilioinguinal-transversus abdominis plane (I-TAP) nerve block with liposomal bupivacaine for cesarean delivery analgesia: A randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112390
Enrollment
Unknown
Registered
2025-11-13
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain after cesarean delivery

Interventions

I-TAP Group:patients will receive a combined bilateral transverse abdominis plane (TAP) block and bilateral iliohypogastric-ilioinguinal (IH-II) nerve block. A total of 60 mL of local anesthetic mixtu
TAP Group:Patients will receive an ultrasound-guided bilateral transverse abdominis plane (TAP) block. A total of 60 mL of local anesthetic mixture will be administered, with 30 mL injected on each si
Control Group:Patients in the control group will undergo a standard ultrasound scan and skin preparation. The practitioner will then perform all subsequent steps at the predetermined needle insertion

Sponsors

Obstetrics and Gynecology Hospital of Tongji University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Age 20-40 years old; 2. Gestational age 37-42 weeks; 3. ASA class II-III; 4. Elective cesarean section at our hospital; 5. Single fetus; 6. BMI <= 35 kg/m^2; 7. Voluntarily agree to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Contraindications for neuraxial anesthesia; 2. Coagulation disorders; 3. Infection at the puncture site; 4. Allergy to analgesic drugs (including liposomal bupivacaine, bupivacaine hydrochloride, ropivacaine, sufentanil, hydromorphone, as well as acetaminophen, flurbiprofen lipid); 5. More than three pregnancies; 6. Mothers with a history of drug abuse; 7. Chronic pain or long-term use of other sedative or analgesic drugs before delivery; 8. Known fetal abnormalities; 9. Maternal refusal.

Design outcomes

Primary

MeasureTime frame
Cumulative opioid consumption within 24 hours postoperatively;

Secondary

MeasureTime frame
Cumulative opioid consumption within 48 hours postoperatively;Time to first request for rescue analgesia postoperatively;Postoperative pain score; Nausea and vomiting incidence rate;Incidence of pruritus;Urinary Retention Incidence ;Incidence of motor block;Time to first mobilization;Rate of Successful Breastfeeding Initiation;Maternal Satisfaction Score;Quality of recovery-15;

Countries

China

Contacts

Public ContactXiaobing Hu

Obstetrics and Gynecology Hospital of Tongji Universityal

huxiaobing@51mch.com+86 135 1216 4741

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026